News | Reading Time 3 minutes

Lallemand Health Solutions Opens the SEMiPyP Congress With An Update on IBacilluS+: A Highly Documented Probiotic Formula for Serious Gut Conditions

Lallemand Health Solutions Opens the SEMiPyP Congress With An Update on IBacilluS+:  A Highly Documented Probiotic Formula for Serious Gut Conditions

Sara Caballero Calero, M.Sc. Clinical Research Specialist at the Rosell® Institute from Microbiome and Probiotics by Lallemand, will be the guest speaker at the inauguration conference of the XIII Workshop of the Sociedad Española de Microbiota, Probióticos y Prebióticos (SEMiPyP). The event will be held from June 7 to 9, 2022, at the Palacio de Congresos de Valencia, Spain.

The aim of the presentation is to recap the clinical background and give insights on the ongoing and future studies of Lallemand Health Solutions probiotic formula IBacilluS+, composed of Enterococcus faecium Rosell®-26 and Bacillus subtilis Rosell®-179.

“With over 70 clinical studies on gastrointestinal health including about 6 000 participants, IBacilluS+ is recognized as a safe and effective adjuvant to standard treatments in several gastrointestinal health indications. IBacilluS+ has shown in published meta-analyses that it can increase the remission rate and maintenance in patients with ulcerative colitis and increase overall treatment effectiveness in patients with irritable bowel syndrome including abdominal pain and diarrhea symptoms reduction. Recently, it has been demonstrated and affirmed by Health Canada that IBacilluS+ after proton pump inhibitor can extend the period between relapses in patients with reflux esophagitis (RE) and reduces the risk of small intestinal bacterial overgrowth (SIBO) in patients with RE.” announces Ms. Caballero Calero.

Back to an in-person event the SEMiPyP XIII Workshop will be dedicated to the promotion and dissemination of scientific knowledge and clinical application around the microbiota, probiotics, and prebiotics. “Based on the excellent experience of previous years, we wanted to organize a multidisciplinary meeting that addresses both the questions and doubts of clinicians and health and nutrition professionals, as well as scientists working in the “Diet-Microbiota-Health” area, without forgetting new discoveries and the new generation of probiotics that is coming, mention Gaspar Pérez Martínez, President of the Organizing Committee. The organization has the intention to promote the acknowledge between the health and microbiota, the benefits of using probiotics and prebiotics and its development by the companies in the industry. Also, they have the mission to involve consumers, institutions, and regulatory experts to these purposes.

For more information about the SEMiPyP XIII Workshop visit the conference website

About Sara Caballero Calero, M.Sc.

Sara Caballero Calero is a Clinical Research Specialist within the Clinical Program at the Rosell® Institute from Microbiome and Probiotics by Lallemand. Sara holds a M.Sc. in Genetics and Cell Biology from the Universidad Autónoma de Madrid (Spain) and a B.Sc. in Chemistry from the Universitat de Barcelona (Spain). This academic background, together with over 6 years of experience in clinical research, grants Sara with multidisciplinary key skills relevant to her current role. As a Clinical Research Specialist, her main role is to manage and coordinate clinical trials within the Lallemand Health Solutions portfolio, from conception to end. Sara´s main interest resides in widening the knowledge on probiotics by using innovative approaches or methodologies to ultimately provide benefit to consumers.

About The Rosell® Institute for Microbiome and Probiotics by Lallemand
One of Lallemand Health Solutions’ two research and development centers is located at the National Research Council of Canada in Montreal and develops, in partnership with key scientific experts, research programs to study the human microbiome and better understand the properties, the mechanisms and effects of probiotics to improve or maintain the health of populations, or specific therapeutic areas. The various Lallemand Health Solutions probiotics have already been studied in multiple research programs including 160 clinical studies leading to around 350 scientific publications.

 

CONTACT
Marilou Luneau mluneau@lallemand.com
Content Manager
Lallemand Health Solutions

Published May 30, 2022 | Updated Jan 11, 2024